Sterling Pharma Solutions launches following management buyout
![](/46/pdcnewsitem/04/30/55/Sterling%20Pharma%20Solutions%20site%20in%20Dudley.jpg)
Sterling Pharma Solutions’ site in Dudley, UK.
The CDMO will specialise in delivering API development and manufacturing solutions.
UK-based Sterling Pharma Solutions has formed as an independent contract development and manufacturing organisation (CDMO) following a management buyout (MBO) of the UK-based Dudley site.
Formerly operating as Shasun Pharma Solutions within Strides Shasun, the process of divesting the business to the current management team was completed in September 2016.
Following the MBO, the newly divested business has been rebranded and launched as Sterling Pharma Solutions. The CDMO will specialise in delivering API development and manufacturing solutions to support global pharmaceutical companies across the entire product lifecycle.
The management team will be led by Kevin Cook as CEO. Kevin joined the Dudley site in 1993. He says: “We are delighted to complete the MBO and excited about building a global API services business with roots in the north east of England. Our offering is compelling as we can take projects from proof of concept to commercial scale manufacture all on one site. We also have the capabilities to handle the most hazardous chemical processes safely.
“We have experienced significant growth in the US and Europe in recent years and believe the extensive capabilities at our site, coupled with our heritage in the API services sector, provide us with an excellent foundation to become the leading partner and provider of API services to the pharmaceutical industry.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance